TRANSCENTA-B (06628.HK): First CDMO sale payment received
- The proceeds will be used to replenish the group's general working capital and develop its product pipeline.
- Staff costs and operating expenses are expected to fall in 2027 from 2026 as a result of the CDMO asset disposal.
NewTimeSpace News: On 20 October 2026, Transcenta Holding Limited (stock code: 06628) said the group had received the after-tax net amount of the first instalment of the consideration, RMB 95 million, from the buyer for the disposal of its CDMO assets under the asset purchase agreement; the total consideration is RMB 190 million, subject to the adjustment mechanism set out in the circular.
The buyer is a wholly-owned subsidiary of WuXi Biologics. The proceeds will fund general working capital and pipeline development. Staff costs and operating expenses are expected to fall in 2027 from 2026 because of the disposal, and the handover is ongoing, with further proceeds expected by the end of 2026. Completion and the balance of the consideration remain subject to conditions and may not proceed.
- TRANSCENTA-B (06628.HK): Gets RMB 95m first payment on CDMO asset sale
- TRANSCENTA-B (06628.HK): CLDN18.2 Antibody Patent Granted in China
- TRANSCENTA-B (06628.HK): Proposes disposal of CDMO assets for RMB 190 million to a WuXi Biologics subsidiary, focusing on innovative drug R&D as core business
- CNBM (03323.HK): expects nine-month loss of about RMB 760 million
- C ZENITH CHEM (00362.HK): Listing to Be Cancelled on 20 October
